Bio-based Polypropylene in Medical Devices Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Application (Heart Valve Structures, Surgery Sutures, Surgical Mesh, Others), By Region, Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 11.96 Billion
CAGR (2026-2031)	9.32%
Fastest Growing Segment	Surgery Sutures
Largest Market	North America
Market Size (2031)	USD 20.41 Billion

Market Overview

The Global Bio-based Polypropylene in Medical Devices Market will grow from USD 11.96 Billion in 2025 to USD 20.41 Billion by 2031 at a 9.32% CAGR. Bio-based polypropylene for medical devices is a thermoplastic polymer derived from renewable feedstocks such as sugarcane, corn, or waste oils, designed to provide the same chemical resistance and mechanical performance as fossil-based polypropylene while reducing carbon emissions. The primary drivers fueling this market include the healthcare sector's urgent mandate to lower its environmental footprint and increasing regulatory pressure regarding sustainable procurement. These drivers are distinct from technological trends, as they represent a fundamental structural shift toward supply chain decarbonization. According to European Bioplastics, in 2024, the global bioplastics production capacity reached 2.47 million tonnes, demonstrating the expanding industrial scale required to support these sustainable sourcing demands.

However, a significant challenge impeding broader market expansion is the rigorous validation and requalification process required for medical-grade materials. Replacing conventional polypropylene with a bio-based alternative necessitates extensive testing to ensure biocompatibility and regulatory compliance, which incurs high costs and delays market entry for established manufacturers.

Key Market Drivers

Implementation of stringent regulatory frameworks promoting sustainable materials is the primary catalyst reshaping the Global Bio-based Polypropylene in Medical Devices Market. As healthcare systems strive to decarbonize, procurement policies are aggressively mandating the reduction of Scope 3 emissions, forcing manufacturers to transition from fossil-based inputs to bio-based polymers. This regulatory pressure effectively compels medical device suppliers to adopt renewable materials to ensure compliance and maintain market access. For instance, according to NHS England, from April 2024, the requirement for suppliers to publish a Carbon Reduction Plan was proportionately extended to cover all new procurements, directly obligating device suppliers to demonstrate verified emissions reductions. This shift is critical as, according to Think Global Health, in February 2024, the healthcare sector worldwide contributed about 4.4 percent of all greenhouse gas emissions, underscoring the urgent mandate for such material interventions.

Strategic industry partnerships for bio-material R&D and commercialization are further accelerating market growth by overcoming supply chain and validation barriers. Chemical producers are collaborating directly with medical device manufacturers to develop medical-grade bio-based polypropylene that meets rigorous biocompatibility standards while scaling production capacities. These alliances ensure that bio-based alternatives are not only technically viable but also commercially available in volumes sufficient for mass production. Demonstrating this industrial commitment, according to LyondellBasell, in its 2024 Sustainability Report, the company reaffirmed its goal to produce and market at least 2 million metric tons of recycled and renewable-based polymers annually by 2030. Such capacity expansion, supported by strategic collaborations, is essential for replacing conventional polypropylene in high-volume applications like disposable syringes and packaging.

Download Free Sample Report

Key Market Challenges

The extensive validation and requalification process required for medical-grade materials constitutes a primary obstacle restricting the growth of the bio-based polypropylene market. Medical device manufacturers must adhere to stringent safety standards, meaning that substituting conventional polypropylene with a bio-based equivalent triggers mandatory, comprehensive testing protocols. These protocols involve rigorous biocompatibility assessments and long-term stability trials to prove that the new material poses no risk to patient safety. The substantial capital required for this requalification, coupled with the uncertainty of the approval timeline, forces manufacturers to prioritize established fossil-based supply chains over sustainable alternatives to avoid operational disruptions.

This regulatory bottleneck significantly slows the commercialization rate of bio-based devices, creating a disconnect between raw material availability and actual market adoption. The extended duration required to clear these regulatory hurdles effectively delays the return on investment for companies attempting to decarbonize their portfolios. According to MedTech Europe, in 2024, the average time required to complete the regulatory certification process for modified medical technologies under the Medical Device Regulation was reported to exceed 18 months. Such prolonged lead times discourage manufacturers from integrating bio-based polypropylene, as the delay in market entry creates competitive risks that outweigh the immediate benefits of sustainable procurement.

Key Market Trends

Commercialization of ISCC PLUS Certified Mass Balance Bio-PP is rapidly emerging as a primary trend, allowing medical device manufacturers to integrate sustainable polymers without altering validated production infrastructure. By utilizing a mass balance approach, suppliers attribute bio-based credits to existing fossil-based manufacturing flows, effectively bypassing the capital-intensive need for segregated facilities while ensuring verifiable traceability. This mechanism is critical for the medical sector, as it resolves the economic and logistical barriers of establishing dedicated bio-plants for high-purity grades. According to ISCC System, October 2024, in the 'ISCC Technical Stakeholder Meeting – Circular Economy and Bioeconomy' recap, the organization reported that the number of valid ISCC PLUS certificates globally reached over 4,800, reflecting the surging industrial adoption of this chain-of-custody model to validate sustainable claims.

Simultaneously, the market is undergoing a structural Transition to Second-Generation Waste-Derived Feedstocks, prioritizing residues like used cooking oil and tall oil over first-generation food crops. This shift addresses ethical concerns regarding food supply competition and significantly lowers the lifecycle carbon footprint of the resulting bio-propylene compared to crop-based alternatives. Medical OEMs are increasingly specifying these waste-derived grades to meet strict circular economy goals without compromising the chemical purity required for clinical applications. Demonstrating this supply chain evolution, according to Neste, March 2024, in the 'Annual Report 2023', the company revealed that the share of waste and residue feedstocks averaged 92 percent of its total renewable material inputs, cementing the dominance of non-food sources in the production of renewable hydrocarbons for polymers.

Segmental Insights

The Surgery Sutures segment represents the fastest-growing category within the Global Bio-based Polypropylene in Medical Devices Market. This rapid expansion is primarily driven by the material's high biocompatibility and tensile strength, which are essential for ensuring reliable wound closure and reducing postoperative infection risks. Additionally, the increasing emphasis on sustainability within the global healthcare industry has prompted a shift toward renewable polymer alternatives. The rising volume of surgical procedures and the material's ability to meet strict clinical safety standards, such as ISO 10993 for biological evaluation, further sustain this accelerated demand.

Regional Insights

North America leads the Global Bio-based Polypropylene in Medical Devices Market, supported by its extensive healthcare infrastructure and a strong commitment to environmental sustainability. The region benefits from a favorable regulatory climate where the US Food and Drug Administration promotes the safety and efficacy of renewable materials in clinical applications. Major medical device manufacturers further drive market expansion by investing in research to integrate bio-based polymers into surgical tools and packaging. This dominance is underpinned by substantial healthcare spending and a concerted transition toward reducing carbon emissions through the adoption of green technologies.

Recent Developments

• In October 2025, Borealis AG and Cytiva introduced renewable polyolefin solutions into the manufacturing of laboratory filtration devices. The partnership focused on replacing fossil-based resins with Bornewables™ bio-based polypropylene for products such as the Whatman™ Puradisc and GD/X syringe filters. This transition allowed for a reduction in Scope 3 greenhouse gas emissions for the life sciences company while ensuring the devices met stringent purity and chemical resistance requirements. The collaboration highlighted the feasibility of using renewable materials in critical healthcare and laboratory applications where consistent performance and regulatory compliance are paramount.
• In September 2025, TotalEnergies and CooperVision partnered to incorporate ISCC PLUS-certified renewable polypropylene into the packaging of contact lenses. The initiative involved using bio-based polymers produced from renewable feedstocks, such as vegetable oils, for the manufacturing of blister packs. This collaboration was part of a broader sustainability program aimed at reducing the carbon emissions associated with medical device packaging. By adopting these renewable materials via a mass balance approach, the companies succeeded in improving the environmental profile of the products without altering their protection properties or compromising patient safety.
• In May 2025, Borealis AG announced a collaboration with Sanitas Healthcare to launch the Protect Video Laryngoscope, a medical device designed with a strong focus on sustainability. The device featured a single-use element manufactured from Bornewables™ bio-based polypropylene, a material derived entirely from renewable feedstocks. This development aimed to minimize the environmental footprint of essential medical equipment while maintaining the high clinical performance and safety standards required in healthcare settings. The use of this mass-balance certified material demonstrated a significant step forward in integrating circular polyolefins into complex medical device applications.
• In January 2024, Avient Corporation presented its range of bio-based polymer solutions at Pharmapack 2024 in Paris, explicitly targeting the pharmaceutical packaging and drug delivery sectors. The company highlighted its bio-based polypropylene formulations, which were designed to support healthcare manufacturers in significantly reducing their product carbon footprints. These specialized materials, which included colorants and additives, were certified for sustainability and offered performance characteristics comparable to traditional fossil-based polymers. The showcase emphasized the growing industry demand for eco-friendly alternatives in medical applications, enabling companies to calculate and lower the environmental impact of their devices and packaging solutions.

Key Market Players

• Saudi Basic Industries Corp
• LyondellBasell Industries NV
• Mitsui Chemicals Inc.
• Borealis AG
• Braskem SA
• TotalEnergies SE
• Danimer Scientific Inc
• FAF Kunststofftechnik GmbH & Co KG
• GreenMantra Recycling Technologies Ltd
• Avient Corporation

By Application	By Region
Heart Valve Structures Surgery Sutures Surgical Mesh Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Bio-based Polypropylene in Medical Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Bio-based Polypropylene in Medical Devices Market, By Application:

• Heart Valve Structures
• Surgery Sutures
• Surgical Mesh
• Others

• Bio-based Polypropylene in Medical Devices Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE